World's No 1 blood pressure med goes generic in US
This article was originally published in Scrip
Executive Summary
The US patent on best-selling antihypertensive valsartan and the combination product valsartan plus the diuretic hydrochlorothiazide (Novartis's Diovan/Diovan HCT) expired on Friday, and Mylan has launched its generic version of Diovan HCT. At the same time, Novartis's generics division, Sandoz, has launched an authorised generic version of Diovan HCT. It would appear that no generic version of the monotherapy is yet available in the US, however.